Search results
Results from the WOW.Com Content Network
Enclomifene (INN Tooltip International Nonproprietary Name), or enclomiphene (USAN Tooltip United States Adopted Name), a nonsteroidal selective estrogen receptor modulator of the triphenylethylene group, acts by antagonizing the estrogen receptor (ER) in the pituitary gland, which reduces negative feedback by estrogen on the hypothalamic-pituitary-gonadal axis, thereby increasing gonadotropin ...
Tamoxifen is also used to treat hormonally-responsive breast cancer, but it does so by interfering with the estrogen receptor. However, letrozole is effective only in post-menopausal women, in whom estrogen is produced predominantly in peripheral tissues (i.e. in adipose tissue, like that of the breast) and a number of sites in the brain. [9]
Tibolone can infrequently produce androgenic side effects such as acne and increased facial hair growth. [8] Such side effects have been found to occur in 3 to 6% of treated women. [8] A 2016 Cochrane review has been published on the short-term and long-term effects of tibolone, including adverse effects. [32]
Ormeloxifene was first discovered by Central Drug Research Institute (CDRI) in Lucknow, India. [13] [16] Ormeloxifene was marketed in Delhi in July 1991 and in India in 1992, under the brand names Saheli and Choice-7. [9] [17] Since 2018, Centchroman is provided free-of-cost to the women in India by the government under the brand name Chhaya ...
The conundrum has left women who might benefit from the new drugs at the mercy of health insurance companies. ... they get to a drug that actually is FDA-approved to treat hot flashes,” said Dr ...
There are several FDA-approved weight loss drugs, including semaglutide, orlistat, phentermine-topiramate, naltrexone-bupropion and liraglutide. Metformin is another common medication used off ...
A New Drug Application of bremelanotide for female sexual dysfunction was accepted by the US Food and Drug Administration (FDA) in June 2018, with a Prescription Drug User Fee Act (PDUFA) goal date set for 23 March 2019. [30] It was approved for use in the United States in June 2019. [3] [31] [32]
Side effects include local inflammatory reactions, such as blisters, a burning sensation, skin redness, dry skin, itching, skin breakdown, skin crusting or scabbing, skin drainage, skin flaking or scaling, skin ulceration, sores, swelling, as well as systemic reactions, such as fever, "flu-like" symptoms, headache, and tiredness.